Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials

Abstract

Central Nervous System (CNS)-related safety concerns are major contributors to delays and failure during the development of new candidate drugs (CDs). CNS-related safety data on 141 small molecule CDs from five pharmaceutical companies were analyzed to identify the concordance between rodent multi-parameter neurofunctional assessments (Functional Observational Battery: FOB, or Irwin test: IT) and the five most common adverse events (AEs) in Phase I clinical trials, namely headache, nausea, dizziness, fatigue/somnolence and pain. In the context of this analysis, the FOB/IT did not predict the occurrence of these particular AEs in man. For AEs such as headache, nausea, dizziness and pain the results are perhaps unsurprising, as the FOB/IT were not originally designed to predict these AEs. More unexpected was that the FOB/IT are not adequate for predicting 'somnolence/fatigue' nonclinically. In drug development, these five most prevalent AEs are rarely responsible for delaying or stopping further progression of CDs. More serious AEs that might stop CD development occurred at too low an incidence rate in our clinical dataset to enable translational analysis.

On the Digital Psychopharmacology of Valproic Acid in Mice

“…Today's newest generation of anticonvulsants are intelligently designed through drug discovery programs that combine the latest technologies in high-throughput screening and medicinal chemistry with an array of established anticonvulsant assays (Rogawski and Hanada, 2013;Klitgaard et al, 2016;Wilcox et al, 2020). Still, evaluations of tolerability crudely focus on motor toxicity, which itself poorly correlate with patient complaints of treatment-related somnolence or fatigue (Mead et al, 2016). Similarly, animal studies on teratogenicity focus primarily on structural malformations, and standardized assessments of neurodevelopmental behavioral toxicity have been consistently deferred and/or ignored.…”

Pharmacological safety of Plinia cauliflora (Mart.) Kausel in rabbits

“…Moreover, poisoning by natural products is not uncommon because of the sensitivity of the central nervous system to these agents [39,40]. Thus, the Irwin test is employed to evaluate the effects of a new drug on physiological and behavioral functions [41]; and may alert us to potential safety concerns, including seizure potential, sedation, and motor changes [42].…”

On the Digital Psychopharmacology of Valproic Acid in Mice

“…Today's newest generation of anticonvulsants are intelligently designed through targeted drug discovery programs that combine the latest technologies in high-throughput screening and medicinal chemistry with an array of established anticonvulsant assays 9,63,64 . Still, evaluations of tolerability crudely focus on motor toxicity, which itself may poorly correlate with complaints of somnolence or fatigue 65 . Similarly, animal studies on teratogenicity focus primarily on structural malformations, and standardized assessments of neurodevelopmental behavioral toxicity have been consistently deferred and/or ignored 66 .…”